title: One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.
abstract: BACKGROUND
  Seven-day triple therapy including omeprazole, clarithromycin and amoxicillin has become the treatment of choice for Helicobacter pylori infection. However, 7 days of classical quadruple therapy combining omeprazole, tetracycline, metronidazole and bismuth may be an alternative to triple therapy.
  
  
  OBJECTIVE
  To compare triple vs. quadruple therapy for H.pylori eradication.
  
  
  METHODS
  Three hundred and thirty-nine patients with peptic ulcer and H. pylori infection were included in the study. Patients were randomized to receive omeprazole, 20 mg, amoxicillin, 1 g, and clarithromycin, 500 mg, all b.d., or omeprazole, 20 mg b.d., tetracycline chloride, 500 mg, metronidazole, 500 mg, and bismuth subcitrate, 120 mg, all t.d.s. Cure was defined as a negative urea breath test at least 2 months after treatment.
  
  
  RESULTS
  Per protocol and intention-to-treat cure rates were 86%[95% confidence interval (CI), 80-91%] and 77% (95% CI, 70-83%) for triple therapy, and 89% (95% CI, 82-93%) and 83% (95% CI, 76-88%) for quadruple therapy. No significant differences between the groups were found in the cure rates, compliance or side-effects.
  
  
  CONCLUSIONS
  One-week triple and quadruple therapy show similar results when used as first-line eradication treatment.
authors.affiliation: Digestive Diseases Unit, Corporació Parc Taulí, Sabadell, Barcelona, Spain. xcalvet@cspt.es
authors.forename: X
authors.initials: X
authors.lastname: Calvet
authors.forename: J
authors.initials: J
authors.lastname: Ducons
authors.forename: J
authors.initials: J
authors.lastname: Guardiola
authors.forename: L
authors.initials: L
authors.lastname: Tito
authors.forename: V
authors.initials: V
authors.lastname: Andreu
authors.forename: F
authors.initials: F
authors.lastname: Bory
authors.forename: R
authors.initials: R
authors.lastname: Guirao
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001944:Breath Tests; D017291:Clarithromycin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology*; D013752:Tetracycline / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole